» Articles » PMID: 29145710

Testosterone Replacement in Transgenic Sickle Cell Mice Controls Priapic Activity and Upregulates PDE5 Expression and ENOS Activity in the Penis

Overview
Journal Andrology
Date 2017 Nov 18
PMID 29145710
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD)-associated priapism is characterized by decreased nitric oxide (NO) signaling and downregulated phosphodiesterase (PDE)5 protein expression and activity in the penis. Priapism is also associated with testosterone deficiency, but molecular mechanisms underlying testosterone effects in the penis in SCD are not known. Given the critical role of androgens in erection physiology and NO synthase (NOS)/PDE5 expression, we hypothesized that testosterone replacement to eugonadal testosterone levels reduces priapism by reversing impaired endothelial (e)NOS activity and molecular abnormalities involving PDE5. Adult male transgenic Berkeley sickle cell (Sickle) and wild-type (WT) mice were implanted with testosterone pellets, which release 1.2 μg testosterone/day for 21 days, or vehicle. After 21 days, animals underwent erectile function assessment followed by collection of blood for serum testosterone measurements, penes for molecular analysis, and seminal vesicles as testosterone-responsive tissue. Serum testosterone levels were measured by radioimmunoassay; protein expressions of PDE5, α-smooth muscle actin, eNOS and nNOS, and phosphorylation of PDE5 at Ser-92, eNOS at Ser-1177, neuronal (n) NOS at Ser-1412, and Akt at Ser-473 were measured by Western blot in penile tissue. Testosterone treatment reversed downregulated serum testosterone levels and increased (p < 0.05) the weight of seminal vesicles in Sickle mice to levels comparable to that of WT mice, indicating restored testosterone levels in Sickle mice. Testosterone treatment reduced (p < 0.05) prolonged detumescence in Sickle mice and normalized downregulated P-PDE5 (Ser-92), PDE5, P-eNOS (Ser-1177), and P-Akt (Ser-473) protein expressions in the Sickle mouse penis. Testosterone treatment did not affect P-nNOS (Ser-1412), eNOS, nNOS, or α-smooth muscle actin protein expressions in the Sickle mouse penis. In conclusion, in the mouse model of human SCD, increasing testosterone to eugonadal levels reduced priapic activity and reversed impaired Akt/eNOS activity and PDE5 protein expression in the penis.

Citing Articles

Idiopathic recurrent ischemic priapism: a review of current literature and an algorithmic approach to evaluation and management.

Yarak N, Khoury J, Coloby P, Bart S, Abdessater M Basic Clin Androl. 2024; 34(1):21.

PMID: 39627696 PMC: 11616154. DOI: 10.1186/s12610-024-00237-y.


Sympathetic hypoactivity leads to hypocontractility of the corpus cavernosum in sickle cell mice: a mechanism contributing to priapism.

Silveira T, Pereira D, Calmasini F, Costa F, Burnett A, Silva F Int J Impot Res. 2024; .

PMID: 39592756 DOI: 10.1038/s41443-024-00997-1.


Targeting heme in sickle cell disease: new perspectives on priapism treatment.

Silveira T, Calmasini F, de Oliveira M, Costa F, Silva F Front Physiol. 2024; 15:1435220.

PMID: 39086934 PMC: 11288928. DOI: 10.3389/fphys.2024.1435220.


Soluble guanylate cyclase stimulators and activators: new horizons in the treatment of priapism associated with sickle cell disease.

Pereira D, Silveira T, Calmasini F, Silva F Front Pharmacol. 2024; 15:1357176.

PMID: 38384294 PMC: 10879333. DOI: 10.3389/fphar.2024.1357176.


The effect of red blood cell disorders on male fertility and reproductive health.

Naelitz B, Khooblall P, Parekh N, Vij S, Rotz S, Lundy S Nat Rev Urol. 2024; 21(5):303-316.

PMID: 38172196 DOI: 10.1038/s41585-023-00838-8.


References
1.
Donaldson J, Davis N, Davies J, Rees R, Steinbrecher H . Priapism in teenage boys following depot testosterone. J Pediatr Endocrinol Metab. 2013; 25(11-12):1173-6. DOI: 10.1515/jpem-2012-0270. View

2.
Cai J, Wen J, Jiang W, Lin J, Hong Y, Zhu Y . Androgen actions on endothelium functions and cardiovascular diseases. J Geriatr Cardiol. 2016; 13(2):183-96. PMC: 4854959. DOI: 10.11909/j.issn.1671-5411.2016.02.003. View

3.
Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M . Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004; 145(5):2253-63. DOI: 10.1210/en.2003-1699. View

4.
Fu S, Tar M, Melman A, Davies K . Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells. FASEB J. 2014; 28(8):3633-44. PMC: 4101653. DOI: 10.1096/fj.13-248708. View

5.
Parshad O, Stevens M, Preece M, Thomas P, Serjeant G . The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J. 1994; 43(1):12-4. View